Investor Presentation: First Nine Months of 2020
34
Investor presentation First nine months of 2020
Novo NordiskⓇ
Class
HbA1c Hypoglycaemia Weight
change
change
risk
CV risk
reduction
Metformin
1.5
No
Neutral
Minimal
GLP-1s have positive effects beyond glycaemic control and
treatment guidelines now reflect the CV risk benefits.
Medications for treatment of type 2 diabetes
ADA/EASD diabetes treatment guidelines for second-line
treatment with established ASCVC or CKD
First-line therapy is metformin and lifestyle management.
If HbA₁ above target, proceed as below
NO
Without
established
ASCVD or CKD
Established ASCVD or CKD
YES
Sulfonylurea
1.5
Yes
Gain
None
ASCVD predominates
TZDS
0.5 -1.4
No
Gain
Varies
HF OR CKD
predominant
DPP-IV inhibitors
0.6-0.8
No
Neutral
Neutral
GLP-1
with proven CVD
benefit*
SGLT-2
with proven CVD
benefit*,
if eGFR adequate
SGLT-2 inhibitors
0.5-0.9
No
Loss
Varies
EITHER/OR
GLP-1
1.0-1.8
No
Loss
Varies
Long-acting insulin
1.5-2.5
Yes
Gain
TG and HDL
Fast-acting insulin
1.5-2.5
Yes
Gain
TG and HDL
*Proven CVD benefit means it has label indication of reducing CVD events. For GLP-1 strongest evidence for
liraglutide>semaglutide>exenatide extended release. For SGLT-2 evidence modestly stronger for empagliflozin>canagliflozin.
ASCVD: atherosclerotic cardiovascular disease; CKD: chronic kidney disease; CV: cardiovascular; CVD: cardiovascular disease;
CVOT: cardiovascular outcome trial; DPP-4: dipeptidyl peptidase-4 inhibitor; eGFR: estimated glomerular filtration rate; GLP-1:
glucagon-like peptide-1 receptor agonist; HF: heart failure; SGLT-2: sodium glucose co-transporter-2 inhibitor
If HbA1c above target
If further intensification is required or patient is now unable to
tolerate GLP-1 and/or SGLT-2, choose agents demonstrating CV
safety...
Sources: Adapted from: Nathan DM, et al. Diabetes Care. 2006; 29: 1963-1972; Nathan DM, et al. 2007;30:753-
759; Nathan DM, et al. Diabetes Care. 2008;31:173-175. ADA. Diabetes Care. 2008; 31:S12-S54. WelChol PI.
1/2008. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes
Association (ADA) and the European Association for the Study of Diabetes (EASD)View entire presentation